Forward Looking Statement This presentation contains "forward looking statements" regarding the Company within the meaning of applicable securities legislation, including statements as to future events, results and plans. Forward-looking statements are sometimes but not always identified by such words as "targeted", "can", "will", "anticipates", "projects", "expects", "intends", "likely", "plans", "should", "could" or "may" or grammatical variations thereof. These include, without limitation, statements wit ...

Financial Performance & Growth - Mako generated revenues of US$111.9 million TTM and US$67.3 million in 1H 2025[7] - Adjusted EBITDA was US$55.7 million TTM[9], with US$48.6 million in EBITDA[55] - Net income reached US$23.3 million TTM and US$18.2 million in 1H 2025[7,55] - The company sold 34,695 oz of Au in 2023 and 39 Koz of Au in 2024[7] Asset Development & Expansion - Mako intends to acquire Mt Hamilton Project for approximately US$40 million[9] - Eagle Mountain Project PEA highlights potential for production of +60k oz/year Au[9] - San Albino mine is permitted up to 1,000tpd[43] Capital Structure & Investments - Mako's market capitalization is US$436 million[10] - The company has US$60.3 million in cash and no debt[10] - US$2.9 million in share repurchases in TTM[9]

Company Overview - Tidewater has the largest OSV fleet in the world, with 209 owned vessels[10] - The company has a significant number of hybrid vessels, totaling 18[10] - Tidewater's fleet has a high specification, with approximately 68% of OSVs meeting high standards[10] - The company boasts strong liquidity, exceeding $680 million[10] - The average age of Tidewater's vessels is 13 years[10] - The company's estimated EBITDA for 2025 is approximately $552 million[10] - Tidewater's market capitalization stands at $2.7 billion[10] - The net debt to 2025E EBITDA ratio is 0.4x[10] Market Overview - Global shipyard capacity has decreased by approximately 57%[67] - Approximately 37% of the active OSV fleet will age beyond 25 years over the next decade[76] Financials - Tidewater refinanced its debt in July 2025, issuing $650 million in senior unsecured notes due in July 2030[95]

Financial Performance - Revenue for Q3 2025 was $1.6 million, compared to $4.9 million in the same quarter last year[14] - Gross profit in Q3 2025 was $0.5 million, representing 31% of revenue, compared to $0.7 million (14% of revenue) in the same period of the prior year[14] - Adjusted EBITDA was negative $5.9 million for the period ended September 30, 2025, compared to negative $0.8 million in the same period of the prior year[14] - Net loss from continuing operations was $10.4 million, compared to a net loss of $6.0 million for the same quarter last year[14] - As of September 30, 2025, cash and cash equivalents totaled $33.1 million, and outstanding debt was $3.9 million with a maturity date of September 2026[15] Cespira Business Unit - Cespira generated $19.3 million in revenue in Q3 2025, up 19% from the same period last year[15] - Cespira's gross profit was negative $1.1 million for Q3 2025, compared to negative $0.2 million in Q3 2024[15] Strategic Focus - The company plans a 60% reduction in Capex and a 15% reduction in SG&A in 2026[26] - The global heavy-duty truck market is expected to reach 1.95 million units in 2025[24]

Financial Performance & Growth - RadNet's Q3 2025 revenue increased by 13.4% compared to Q3 2024, achieving record quarterly revenue[22] - The company's adjusted EBITDA margin increased by 26 basis points to 16.2%[20] - RadNet has a strong liquidity position with $804.7 million in cash balance and a net debt to adjusted EBITDA leverage ratio of approximately 1.0x[22] - The company anticipates a revenue CAGR of +11% to +13% and a Digital Health revenue CAGR of ~30% from 2025 to 2028[788] Procedural Volume Growth - MRI procedural volume grew by 14.8% in aggregate and 11.5% on a same-center basis[21] - CT procedural volume increased by 9.4% in aggregate and 6.7% on a same-center basis[21] - PET/CT procedural volume experienced a significant increase of 21.1% in aggregate and 14.9% on a same-center basis[21] Technology & Innovation - Deep Learning Reconstruction (DLR) allows for 50-75% faster MRIs while improving image quality[43] - RadNet performs over 2 million mammograms a year, representing 5% of all mammograms in the US[283] - AI-assisted reads found clinically significant prostate cancer in 24% of men when MRI was deemed negative by the radiologist[343] Market Trends & Opportunities - The national imaging market is estimated at $100 billion in 2025[568] - The company's joint venture revenue is projected to reach ~$800 million in 2025, reflecting a CAGR of 19.1% from 2022 to 2025[607] - The company has seen ~18x increase in Cardiac CTA volume from Jan 2020 to October 2025[506]

Pipeline and Programs - BioNTech has 16 clinical programs in oncology and 7 clinical programs in infectious diseases[14] - Pumitamig, a PD-L1 x VEGF-A bispecific antibody, showed an objective response rate (ORR) of 76.9% in PD-L1 negative, 56.3% in PD-L1 low, and 100% in PD-L1 high TNBC patients when combined with chemotherapy[57] - In EGFRmut NSCLC post EGFR TKI, pumitamig combined with chemo showed an ORR of 39.3% in PD-L1 negative, 60.9% in PD-L1 low, and 92.3% in PD-L1 high patients[60] - BNT324/DB-1311, an anti-B7H3 ADC, showed an ORR of 54.5% at 6 mg/kg and 58.8% at 9 mg/kg in SCLC patients who received prior IO but no prior TOP1i[209] Clinical Trials and Strategy - BioNTech is executing a three-wave strategy for Pumitamig, including foundational registrational trials, expanding into multiple disease indications, and synergistic novel-novel combinations[64] - BioNTech has over 1,400 patients dosed across pumitamig monotherapy and chemo combination studies[141] - A Phase 3 trial is evaluating Gotistobart versus docetaxel in 600 patients with 2L squamous non-small cell lung cancer[83, 179] Financials and Partnerships - BioNTech increased its 2025 revenue guidance to a range of €26 to €28 billion[437] - BioNTech has €167 billion in cash, cash equivalents, and securities[437] - BioNTech's partnership with BMS includes $35 billion upfront and non-contingent payments, plus $76 billion in milestone payments for Pumitamig[443]

Company Overview - Ralliant has approximately 7,000 team members and 21 manufacturing sites[19] - The company serves around 90,000 customers[19] - Ralliant's revenue is over $2 billion[19] - The company possesses around 2,200 active patents[19] Financial Targets - The company targets revenue growth of 3-5% through the cycle[19, 37] - Adjusted EBITDA margin target is in the low to mid-20s percentage range[19, 37] - Free cash flow (FCF) conversion target is above 95%[19] - Net leverage target is 1.5x – 2.0x[19] - The company aims to generate over $1 billion of cumulative FCF through 2028[37] Revenue Breakdown by Segment - Test & Measurement segment accounts for approximately 60% of revenue[19, 22] - Sensors & Safety Systems segment accounts for approximately 40% of revenue[19, 22] Revenue Breakdown by End Market - Diversified Electronics represents 22% of revenue[19, 23] - Industrial Manufacturing represents 19% of revenue[19, 23] - Defense & Space represents 16% of revenue[19, 23] - Utilities represents 13% of revenue[19, 23] - Communications represents 13% of revenue[19, 23] - Semiconductor represents 9% of revenue[19, 23] - Other (including Food and Beverage, Healthcare, and HVAC) represents 9% of revenue[19, 23, 24]

Advanced Noninvasive Neurostimulation Treatments for Mental Health Disorders Investor Deck November 2025 Nasdaq/TASE: BWAY Investor Deck | November 2025 Safe Harbor and Non-GAAP/IFRS Financial Measures This presentation does not constitute an offer orinvitation to sell orissue, or any solicitation of an offerto subscribe for or acquire, any securities ofthe Company, norto participate in any investment. This presentation shall not constitute advertising or be construed as commercial or promotional in nature. ...

Financial Performance - Q3 2025 revenue was $152.5 million[6], down 11.2% year-over-year[14] - Adjusted EBITDA increased 7% year-over-year to $4.6 million[14] - Adjusted EPS was ($0.14) per diluted share[6] - Adjusted gross margin improved to 12.1%, up 10 bps sequentially from Q2 2025 and 370 bps from Q4 2024[6] - Year-to-date free cash flow was $25 million, an improvement of $14 million over the prior year[6] Segment Performance - Global Seating revenue decreased 10% year-over-year in Q3 2025 to $68.7 million[16], but adjusted operating income increased by $3.7 million[22] - Global Electrical Systems revenue increased 6% year-over-year in Q3 2025 to $49.5 million[24], and adjusted operating income increased by $1.6 million[30] - Trim Systems and Components revenue decreased 29% year-over-year in Q3 2025 to $34.3 million[32], with an adjusted operating income decline of $4.4 million[35] Outlook and Strategy - The company expects free cash flow of at least $30 million in 2025[50] - The company is targeting a $30 million improvement in working capital in 2025[48] - The company updated its fiscal 2025 outlook, projecting net sales of $640-$650 million and adjusted EBITDA of $17-$19 million[49]

Acquisition Overview - Parker Hannifin Corporation is acquiring Filtration Group Corporation [1] - The transaction consideration is $9.25 billion on a cash-free, debt-free basis [10] - The acquisition is expected to close within six to twelve months [10] Financial Impact and Synergies - Filtration Group is expected to have $2 billion in sales in CY2025 with a 23.5% adjusted EBITDA margin [9, 10] - The acquisition is expected to be accretive to organic growth, synergized EBITDA margin, adjusted EPS, and cash flow [9, 10] - $220 million of cost synergies are expected by the end of year three, leveraging "The Win Strategy" [9, 10, 19] - The company is targeting >30% adjusted EBITDA margin expected by end of year three [10] Market Expansion and Portfolio Transformation - The acquisition expands Parker's presence in Life Sciences (28%), HVAC/R (23%), and In-Plant & Industrial (20%) market verticals [9, 12] - It increases Parker Filtration aftermarket sales by 500 bps [9, 13] - Post-acquisition, the proforma FY26 sales are estimated to be ~$23 billion [21]